AU2016319111B2 - Azophenols as ERG oncogene inhibitors - Google Patents
Azophenols as ERG oncogene inhibitors Download PDFInfo
- Publication number
- AU2016319111B2 AU2016319111B2 AU2016319111A AU2016319111A AU2016319111B2 AU 2016319111 B2 AU2016319111 B2 AU 2016319111B2 AU 2016319111 A AU2016319111 A AU 2016319111A AU 2016319111 A AU2016319111 A AU 2016319111A AU 2016319111 B2 AU2016319111 B2 AU 2016319111B2
- Authority
- AU
- Australia
- Prior art keywords
- erg
- compound
- protein
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/04—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216839P | 2015-09-10 | 2015-09-10 | |
| US62/216,839 | 2015-09-10 | ||
| PCT/US2016/051098 WO2017044844A1 (en) | 2015-09-10 | 2016-09-09 | Azophenols as erg oncogene inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016319111A1 AU2016319111A1 (en) | 2017-10-19 |
| AU2016319111B2 true AU2016319111B2 (en) | 2021-05-06 |
Family
ID=58240304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016319111A Ceased AU2016319111B2 (en) | 2015-09-10 | 2016-09-09 | Azophenols as ERG oncogene inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10238639B2 (https=) |
| EP (1) | EP3347001B1 (https=) |
| JP (1) | JP6865174B2 (https=) |
| AU (1) | AU2016319111B2 (https=) |
| CA (1) | CA2981188C (https=) |
| WO (1) | WO2017044844A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017044844A1 (en) | 2015-09-10 | 2017-03-16 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Azophenols as erg oncogene inhibitors |
| WO2021257966A1 (en) * | 2020-06-19 | 2021-12-23 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Erg oncogene inhibitors |
| CN113616645A (zh) * | 2021-08-27 | 2021-11-09 | 深圳先进技术研究院 | 一种噻唑基重氮萘酚类化合物在制备治疗恶性脑胶质瘤药物中的应用 |
| WO2023097119A2 (en) * | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0738075B2 (ja) * | 1986-12-23 | 1995-04-26 | 住友化学工業株式会社 | 新規なフオトレジスト組成物 |
| KR100295371B1 (ko) * | 1996-12-27 | 2001-11-26 | 사토 히로시 | 광기록매체 |
| WO2010101994A2 (en) * | 2009-03-03 | 2010-09-10 | The Regents Of The University Of Michigan | Gene fusion targeted therapy |
| WO2015048718A2 (en) | 2013-09-30 | 2015-04-02 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Inhibition of thymine dna glycosylase in the treatment of cancer |
| WO2017044844A1 (en) | 2015-09-10 | 2017-03-16 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Azophenols as erg oncogene inhibitors |
-
2016
- 2016-09-09 WO PCT/US2016/051098 patent/WO2017044844A1/en not_active Ceased
- 2016-09-09 CA CA2981188A patent/CA2981188C/en active Active
- 2016-09-09 AU AU2016319111A patent/AU2016319111B2/en not_active Ceased
- 2016-09-09 US US15/561,626 patent/US10238639B2/en active Active
- 2016-09-09 JP JP2017550884A patent/JP6865174B2/ja active Active
- 2016-09-09 EP EP16845184.7A patent/EP3347001B1/en active Active
-
2019
- 2019-02-15 US US16/277,410 patent/US20190336485A1/en not_active Abandoned
-
2021
- 2021-01-26 US US17/158,930 patent/US11648239B2/en active Active
Non-Patent Citations (2)
| Title |
|---|
| KATSUMI DOH-URA ET AL, "Chelating Compound, Chrysoidine, Is More Effective in Both Antiprion Activity and Brain Endothelial Permeability Than Quinacrine", CELLULAR & MOLECULAR NEUROBIOLOGY, (2007-01-19), vol. 27, no. 3, pages 303 - 316 * |
| TOHRU SAITOH ET AL, "Solute partition study in aqueous sodium dodecyl sulfate micellar solutions for some organic reagents and metal chelates", MIKROCHIMICA ACTA., AT, (1992-01-01), vol. 106, no. 1-2, pages 91 - 99 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190336485A1 (en) | 2019-11-07 |
| AU2016319111A1 (en) | 2017-10-19 |
| EP3347001A1 (en) | 2018-07-18 |
| US10238639B2 (en) | 2019-03-26 |
| WO2017044844A1 (en) | 2017-03-16 |
| JP6865174B2 (ja) | 2021-04-28 |
| US20210299106A1 (en) | 2021-09-30 |
| US11648239B2 (en) | 2023-05-16 |
| CA2981188C (en) | 2024-05-28 |
| EP3347001A4 (en) | 2019-05-08 |
| JP2018526320A (ja) | 2018-09-13 |
| HK1258415A1 (en) | 2019-11-08 |
| EP3347001B1 (en) | 2023-07-26 |
| CA2981188A1 (en) | 2017-03-16 |
| US20180169074A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11648239B2 (en) | Azophenols as ERG oncogene inhibitors | |
| EP3288552A1 (en) | Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor | |
| CA2983011A1 (en) | Methods for treating cancer | |
| Hu et al. | Telmisartan prevents angiotensin II‐induced endothelial dysfunction in rabbit aorta via activating HGF/M et system and PPAR γ pathway | |
| AU2015229379B2 (en) | Novel inhibitors for ERG oncogene positive cancers | |
| HK1258415B (en) | Azophenols as erg oncogene inhibitors | |
| JP6489517B2 (ja) | ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬 | |
| EP3893861B1 (en) | Treatment and prevention of glioblastoma | |
| KR101599259B1 (ko) | 혈관 신생작용 관련 질환 치료를 위한 HIF-1α 저해 화합물 | |
| CA3072389C (en) | Selective beta2-adrenergic receptor antagonist for treating von hippel-lindau disease | |
| Liu et al. | Genetic alterations in the PI3K/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mTOR | |
| CA3072389A1 (en) | Selective beta2-adrenergic receptor antagonist for treating von hippel-lindau | |
| JPWO2014046125A1 (ja) | トロンビン受容体アンタゴニストを有効成分とする肺高血圧症の予防治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |